FELDAN CONGRATULATES SCGE PROGRAM FOR NATURE ARTICLE

Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for publishing their work in the journal Nature. Feldan is honoured to be part of this initiative alongside its long-standing collaborator, Dr. Paul McCray of the University of Iowa.  

https://www.nature.com/articles/s41586-021-03191-1 

About the collaboration between Dr. McCray and Feldan Therapeutics: 
The lungs, which evolved to be resistant to many outside stimuli, are widely recognized as difficult organs to deliver drugs into. The respiratory epithelium presents barriers due to its specialized cell types, secreted host defense factors and mucociliary transport.   

Through their work, Dr. Paul McCray and Feldan Therapeutics have demonstrated that the Feldan Shuttle technology enables the delivery of functional proteins and CRISPR nucleases to human airway epithelial cells, which opens the door to the development of revolutionary therapies in the pulmonary field. 

In 2018, the collaboration between Dr. McCray and Feldan was bolstered by a $4-million (US) subsidy from the SCGE program to carry out a five-year project aimed at optimizing the Feldan Shuttle technology to deliver CRISPR nucleases to in vivo models.  

In 2019, another Collaboration Opportunity Fund from the SCGE program allowed Feldan to expand its research into the use of base editors to modify primate airway cells, in collaboration with the teams of Dr. David Liu (Harvard University) and Dr. Alice Tarantal (University of California, Davis). 

For more details:
https://www.newswire.ca/news-releases/university-of-iowa-and-feldan-therapeutics-awarded-grant-by-the-national-institutes-of-health-697187691.html 
https://www.nature.com/articles/s41467-019-12922-y